BioAssay Systems

Executive Summary

BioAssay Systems is a US-based diagnostics company founded in 2003 that provides high-throughput biochemical assay kits to the life sciences industry. Leveraging over 50 years of combined founder experience in drug discovery, the company offers simple and high-performance solutions for biopharmaceutical companies and academic researchers. Its product portfolio covers a range of assays, including those for oxidative stress, metabolic function, and cell-based assays, supporting applications from basic research to drug development. With a global customer base, BioAssay Systems positions itself as a reliable supplier of cost-effective, ready-to-use kits that reduce assay time and improve reproducibility. The company operates in the competitive life science tools market, differentiated by its focus on convenience and performance in high-throughput formats. As a private entity with no disclosed funding, BioAssay Systems likely generates steady organic revenue from kit sales. Growth opportunities lie in expanding its assay menu for emerging biomarkers, such as those in immuno-oncology or neurodegenerative diseases, and in forming strategic partnerships with diagnostic developers. Given the increasing demand for efficient drug screening tools, the company is modestly positioned to capture market share. However, its lack of recent major news or funding rounds limits visibility. Overall, BioAssay Systems appears to be a stable but low-profile player in the diagnostics space.

Upcoming Catalysts (preview)

• Q4 2026Launch of a novel high-sensitivity assay kit for a key biomarker (e.g., cytokines or exosomes)60% success
• Q3 2026Strategic partnership with a mid-sized biopharma for assay supply40% success
• Q2 2026Receipt of ISO 13485 certification to expand regulated markets70% success